Premium
Amrinone reverses bupivacaine‐induced regional myocardial dysfunction
Author(s) -
Fujita Y.
Publication year - 1996
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/j.1399-6576.1996.tb04387.x
Subject(s) - amrinone , medicine , bupivacaine , anesthesia , perfusion , cardiology , toxicity , hemodynamics
Amrinone has been shown to have therapeutic effects on bupivacaine‐induced cardiovascular toxicity, but its exact effects on the heart are not well understood. This study evaluated the regional myocardial effect of amrinone on bupivacaine‐induced cardiovascular toxicity in in situ beating hearts in 10 dogs using a selective coronary perfusion and sono‐micrometry. In the control group, bupivacaine was administered into the left anterior descending coronary artery (LAD) for 15 min at tour steps: baseline, step 1, step 2 and step 3, (calculated LAD plasma concentrations; 0, 5, 5 and 10 μg·ml ‐1 , respectively). In the amrinone group, amrinone (5 μg·ml ‐1 ) was simultaneously infused at steps 2 and 3 in addition to bupivacaine infusions. Regional myocardial function of the LAD supplied area was evaluated by analysis of the left ventricular pressure‐segment length loop. In the control group, systolic shortening decreased from the baseline (10.5±1.3%, mean ± SEM) to step 3 (0.1±1.3%), and post‐systolic shortening increased from the baseline (18.0±3.7%) to step 3 (52.3±5.5%) dose‐dependently. In contrast, with amrinone infusion at steps 2 and 3, both variables returned to near baseline values. These results indicate that amrinone reverses bupivacaine‐induced regional myocardial dysfunction.